Company profile: Genespire
1.1 - Company Overview
Company description
- Provider of transformative gene therapies for genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Offers Immune Shielded Lentiviral Vectors for direct liver use enabling long-term hepatocyte-specific expression for one-time treatments, and an Advanced Gene Editing Platform enabling high-efficacy, permanent targeted gene integration in T-cells and HSPCs.
Products and services
- Advanced Gene Editing Platform: Custom-engineered system enabling high-efficacy, permanent targeted integration of therapeutic genes into T-cells and HSPCs in patient blood, applicable across a wide range of genetic diseases
- Immune Shielded Lentiviral Vectors (ISLVs): Liver-targeted assemblies engineered for direct hepatic delivery, yielding long-term, stable hepatocyte-specific therapeutic gene expression enabling one-time treatments for diseases requiring life-long liver expression
- Transformative Gene Therapies: Indication-focused programs developing gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Genespire
Endpoint Health
HQ: United States
Website
- Description: Provider of precision immunology solutions, including targeted therapeutics tailored to patient biology for immune-mediated diseases, companion diagnostics to personalize treatment, a precision immunology ecosystem with pharma, biotech, diagnostics providers and clinical data registries, and clinical collaborations with over 60 global health systems to develop precision therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endpoint Health company profile →
Citryll
HQ: The Netherlands
Website
- Description: Provider of pharmaceutical drugs targeting Neutrophil Extracellular Traps (NETs) to treat autoimmune and inflammatory diseases such as SLE, RA, vasculitis, and IPF. Offers CIT-013, a therapeutic antibody; conducts NETosis inhibition research to reduce auto-antigen release and clear pro-inflammatory NETs; advances clinical development with first-in-human and planned Phase 2a trials in RA and hidradenitis suppurativa; and pursues collaboration opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Citryll company profile →
Agomab Therapeutics
HQ: Belgium
Website
- Description: Provider of molecular therapies to regenerate damaged tissues and restore organ function in fibrotic, inflammatory, autoimmune and degenerative diseases. Programs include agomAbs that stimulate repair and small-molecule ALK5 inhibitors: AGMB-129 (oral GI-restricted for fibrostenosing Crohn’s) and AGMB-447 (inhaled lung-restricted for IPF), plus HGF-mimetic full/partial MET agonist antibodies AGMB-101/102, and expanded access/compassionate use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agomab Therapeutics company profile →
MyMD Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage pharmaceuticals, including MYMD-1, an oral TNF-alpha inhibitor to regulate the immune system, reduce chronic inflammation, and potentially treat autoimmune and age-related conditions; and Supera-CBD, a synthetic cannabidiol analog targeting CB2 receptors for anxiety, chronic pain, seizures, and potentially addiction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MyMD Pharmaceuticals company profile →
Upstream Bio
HQ: United States
Website
- Description: Provider of antibody therapies targeting the TSLP receptor, developing verekitug (UPB-101), a monoclonal antibody in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and conducting research on Thymic Stromal Lymphopoietin (TSLP) as a driver of inflammatory responses in allergic and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Upstream Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Genespire
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Genespire
2.2 - Growth funds investing in similar companies to Genespire
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Genespire
4.2 - Public trading comparable groups for Genespire
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →